FGFR2 and endometrial cancer: Aberrant FGFR2 signaling has been linked to tumorigenesis in several cancers, including breast, gastric, and endometrial cancers, through the activation of downstream pathways such as MAPK, PI3K/AKT, and STAT signaling cascades.